Active Ingredient History
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Panobinostat inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Panobinostat's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Panobinostat also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia (Phase 1)
Anemia, Sickle Cell (Phase 1)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Chordoma (Phase 1)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Esophageal Neoplasms (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Graft vs Host Disease (Phase 2)
Head and Neck Neoplasms (Phase 1)
Hematologic Neoplasms (Phase 2)
HIV Infections (Phase 1/Phase 2)
Hodgkin Disease (Phase 3)
Kidney Neoplasms (Phase 1)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2/Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 2/Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Leukemia, Plasma Cell (Phase 2)
Leukemia, T-Cell (Phase 2)
Liver Neoplasms (Phase 1)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2/Phase 3)
Lymphoma, T-Cell, Peripheral (Phase 2)
Medulloblastoma (Early Phase 1)
Melanoma (Phase 1/Phase 2)
Meningioma (Phase 1)
Mesothelioma (Phase 1)
Multiple Myeloma (Phase 4)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Carcinoma (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms ()
Neuroendocrine Tumors (Phase 2)
Oncogenes (Phase 2)
Pancreatic Neoplasms (Phase 2)
Plasmacytoma (Phase 2)
Polycythemia Vera (Phase 2)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 2)
Rhabdoid Tumor (Phase 2)
Sarcoma (Phase 2)
Sezary Syndrome (Phase 2)
Skin Neoplasms (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Stomach Neoplasms (Phase 2)
Thrombocytopenia (Phase 2)
Thyroid Neoplasms (Phase 2)
Transplantation (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
